July 20, 2023 12:18 PM EDTUpdated 12:54 PM
Pharma
Manufacturing

FDA re­ports short­age of No­vo Nordisk's weight loss drug Sax­en­da

Tyler Patchen

News Reporter

No­vo Nordisk is fac­ing an­oth­er short­age of one of its block­buster drugs; this time it’s the weight loss drug li­raglu­tide, bet­ter known as Sax­en­da. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times